Wedén et al followed up for 10 years in patients with pancreatic cancer and found that survival was 20% (4/20) in patients treated with a k-RAS mutant neoantigen vaccine compared with 0% (0/87) in the control group.37 The study by Schreiber’s group highlights the critical role of MHC-II in the presentation of neoantigens. This evidence concerns the gene KRAS and familial pancreatic carcinoma.